Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951625 · ClinicalTrials.gov registry record · Phase 2
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
A Phase 2 study of Heart Failure, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 456
- Enrollment target
- 20
- Study locations
NCT01951625 is a Phase 2 study of Heart Failure that has completed, run by Bayer. The registered enrollment target is 456 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT01951625, a Phase 2 study of Heart Failure, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 456 participants
- Enrollment target
- 20
- Study locations
Study Summary
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vericiguat (BAY1021189) (1.25 mg)
- DRUG Vericiguat (BAY1021189) (5 mg)
Study Locations (20)
Florida
- - Fort Lauderdale
- - Jacksonville
- - Naples
Georgia
- - Atlanta
- - Macon
Ohio
- - Columbus
- - Fairfield
Tennessee
- - Germantown
- - Nashville
California
- - Fountain Valley
Delaware
- - Wilmington
Louisiana
- - New Orleans
Michigan
- - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2013-11-29 |
| Est. Completion | 2015-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01951625
The ClinicalTrials.gov registry entry for NCT01951625 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (78% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01951625 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Georgia, Ohio.
Frequently Asked Questions
What is clinical trial NCT01951625 about?
NCT01951625 is a clinical study titled "Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)". Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced ejection fraction (HFrEF).
What is the current status of trial NCT01951625?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 456 participants. The study started on 2013-11-29. Estimated completion is 2015-06-09.
What conditions does trial NCT01951625 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT01951625?
The interventions under investigation include: Placebo (DRUG), Vericiguat (BAY1021189) (1.25 mg) (DRUG), Vericiguat (BAY1021189) (5 mg) (DRUG).
Who is sponsoring clinical trial NCT01951625?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01951625 being conducted?
This trial has 20 study locations across California, Delaware, Florida, Georgia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
RECRUITING · Phase 2
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.